FDA Cleared Robotic Exoskeleton for Patients from Stroke & Spinal Cord Injury

Ekso Bionics , a robotic exoskeleton company, announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its Ekso GT robotic exoskeleton for use in the treatment of individuals with hemiplegia due to stroke, individuals with spinal cord injuries at levels T4 to L5, and individuals with spinal cord injuries at levels of T3 to C7 (ASIA D), in accordance with device’s labeling. The Ekso GT is the first exoskeleton cleared by the FDA for use with stroke patients.

More info available from Ekso Bionics website by clicking this link.

Earlier in news: FDA OKs Parker Hannifin's Indego Exoskeleton for Both Clinic and Home Use